Loading people...
Dirk Landgraf is a Principal at SV Health Investors in Boston, Massachusetts, where he focuses on investments for the Dementia Discovery Fund. Since joining the firm in 2020, he has managed early-stage biotechnology investments and supported portfolio companies through major transactions, including Merck's acquisition of Caraway Therapeutics for up to $610 million. Previously, he served as an Associate Director in External Innovation at Biogen, leading scientific due diligence for therapeutics targeting Alzheimer's disease, multiple sclerosis, and brain drug delivery. His academic background includes a postdoctoral fellowship studying protein misfolding in neurodegeneration at the Whitehead Institute at MIT, a doctorate in systems biology from Harvard Medical School, and degrees from the Technical University of Munich. Landgraf leverages his extensive scientific training to identify and scale novel central nervous system therapeutics from early discovery through commercialization.
Dirk Landgraf is a Principal at SV Health Investors, a prominent venture capital firm dedicated to advancing healthcare innovation. In his role, Dirk is a key contributor to the firm's investment strategy, particularly within the dynamic fields of biotechnology and pharmaceuticals. He is instrumental in identifying promising early-stage and growth-stage companies, guiding them from concept to market.
His primary focus lies in pioneering new therapeutic approaches across a range of critical disease areas. This includes oncology, immunology, neuroscience, and rare diseases, as well as disruptive platform technologies that have the potential to redefine medical treatment. Dirk is deeply involved in the process of company creation, often working with leading scientists and entrepreneurs to translate groundbreaking research into viable commercial entities. This involves strategic planning, team building, and securing the necessary capital to bring novel therapies to patients.
Before joining SV Health Investors, Dirk honed his expertise in the life sciences sector through various impactful roles. He served as a Principal at Wellington Partners Life Sciences, where he gained significant experience in venture capital investment and portfolio management. Prior to his venture capital career, Dirk held key positions in business development and licensing at major pharmaceutical companies, including Novartis and Roche. These experiences provided him with a comprehensive understanding of drug discovery, development, and commercialization, equipping him with a unique perspective on the challenges and opportunities within the healthcare industry. Academically, Dirk holds a Ph.D. in Molecular Biology, a foundation that underpins his deep scientific acumen and ability to evaluate complex biotechnological innovations.
At SV Health Investors, Dirk leverages his extensive scientific background and investment acumen to identify and support companies poised for significant impact. His work contributes to SV Health Investors' mission of building innovative healthcare companies that address unmet medical needs globally. He plays a vital role in the due diligence process, evaluating scientific merit, market potential, and management teams, ensuring that investments align with the firm's strategic objectives and commitment to patient benefit. His involvement helps shape the future of medicine by fostering the growth of companies developing life-changing therapies.
Dirk Landgraf is a Principal at SV Health Investors, a leading transatlantic venture capital firm focused on healthcare. He specializes in early-stage and growth-stage investments in biotechnology and pharmaceutical companies, often involved in new company creation.
Dirk Landgraf primarily invests in early-stage and growth-stage biotechnology and pharmaceutical companies. His focus areas include oncology, immunology, neuroscience, rare diseases, and platform technologies that offer innovative therapeutic solutions.
Dirk Landgraf works as a Principal at SV Health Investors. SV Health Investors is a prominent venture capital firm with offices in Boston and London, dedicated to investing in and building innovative healthcare companies.
